Evidence map›Paper›PMID 37580416›Full record

Trial reportEye (London, England)2024

African American patient-provider communication about glaucoma vision quality-of-life.

Betsy Sleath, Bethany Beznos, Delesha M Carpenter, Donald L Budenz, Kelly W Muir, Maria S Romero, Charles Lee, Gail Tudor, Nacire Garcia, Alan L Robin

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Betsy SleathDivision of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. betsy_sleath@unc.edu.ORCID 0000-0002-8861-6955
Bethany BeznosDivision of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-3301-5423
Delesha M CarpenterDivision of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-2025-8140
Donald L BudenzDepartment of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kelly W MuirDepartment of Ophthalmology, School of Medicine, Duke University, Durham, NC, USA.
Maria S RomeroPhysician CEO, Precision Eye Care, Baltimore, MD, USA.
Charles LeeAlexor, LLC, Durham, NC, USA.
Gail TudorSouthern New Hampshire University, Manchester, NH, USA.
Nacire GarciaDivision of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Alan L RobinWilmer Institute, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0003-1959-8770

Funding

Improving African American glaucoma patient involvement in visits and outcomesR01HS025370 · AHRQ · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SLEATH, BETSY LYNN · 2017 to 2020
$1.6M
AHRQ HHS R01 HS025370
6 · The paper itself

Abstract

BACKGROUND/

objectivesLittle is known about African American patient-provider communication about glaucoma-related quality-of-life. The objectives of this study were to: (a) examine associations between patient socio-demographics and vision quality-of-life, (b) describe the extent to which eye care providers and patients discuss glaucoma-related quality-of-life, and (c) examine associations between patient and provider characteristics, whether the patient was in the intervention or usual care group, and whether the patient and provider discuss one or more glaucoma-related quality-of-life domains.

methodsAdult African American patients with glaucoma who reported non-adherence to glaucoma medications were enrolled from three sites. Patients completed a vision quality-of-life VFQ-25 assessment. Patients were randomized into intervention and control groups with intervention group members receiving a glaucoma question prompt list and watching a video before a provider visit. Audio recordings from these visits were transcribed and assessed for glaucoma-related quality-of-life discussions.

resultsOne hundred and eighty-nine patients were enrolled. Glaucoma-related quality-of-life was discussed during 12.3% of visits (N = 23). Patients initiated discussion 56.5% (N = 13) of the time and providers 43.5% (N = 10) of the time. Patients with worse health literacy (p < 0.001), more depressive symptoms (p < 0.05), and more severe glaucoma (p < 0.001) were significantly more likely to have worse vision-related quality-of-life. Glaucoma-related quality-of-life was significantly more likely to be discussed when African American patients saw African American providers (p < 0.05).

conclusionPatients and providers rarely discussed the patient's glaucoma-related quality-of-life. The intervention did not significantly increase communication about glaucoma-related quality-of-life. Residency programs should consider enhancing training regarding discussing patients' quality-of-life.

Indexed as

Black or African AmericanGlaucomaAdultCommunicationHumansQuality of Life

Identifiers

PMID37580416
PMCPMC10810853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.